The sweeping executive order sets a deadline for drugmakers to lower the cost of prescription drugs in the United States or face new limits over what the government will pay.
People taking Eli Lilly and Co.’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the medications.
The proposal, expected to be announced by President Trump on Monday, will face fierce opposition from the pharmaceutical industry.
The idea, floated by the White House as a way to help pay for the president’s tax cut plan, blindsided the pharmaceutical industry and has prompted a furious lobbying campaign.
CVS Health’s pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.
The U.S. Department of Justice accused the pharmacy of illegally filling millions of prescriptions in the last decade for opioids and other controlled substances.
Roche said Indiana would receive a new manufacturing facility for continuous glucose monitoring and expansion and upgrades at existing pharmaceutical, diagnostics and distribution operations.
By making the expected blockbuster pill in the U.S., Lilly may be able to avoid the impact of Trump’s sweeping tariffs, including possible levies on pharmaceutical products.
Trial data data showed Lilly’s experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer to developing a needle-free alternative to injections.
Trump’s order contains proposals to further lower the cost of insulin, importing more low-cost drugs and streamlining the federal approval process for some drugs.
It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs on the sector.
Pfizer had been hoping the once-daily pill treatment would give it an edge over leading weight-loss treatments like Zepbound from Eli Lilly and Co. and Novo Nordisk’s Wegovy, which are injectable.
Weeks after ordering all Food and Drug Administration employees back into the office, the agency is allowing some of its most prized staffers to work remotely.
The drugmaker accuses Premier Weight Loss of risking patients’ health by selling altered, unsterile versions of its blockbuster drugs Mounjaro and Zepbound.
President Trump’s predecessor, Joe Biden, proposed a rule in late November after Trump won re-election that would have extended coverage of drugs like Zepbound and Wegovy.
Aside from building four new plants, Johnson & Johnson said that it will expand several existing sites.
Members of the Sackler family who own the OxyContin maker Purdue Pharma would hand over the company in the latest plan to settle thousands of lawsuits.
Indianapolis-based Eli Lilly and Co. launched LillyDirect a little more than a year ago and has been ramping up efforts to connect directly with consumers on the platform since.
Novo Nordisk’s new offering follows a direct-to-consumer model that Eli Lilly launched last year.
The results showed that the number of severe adverse events for patients was 54.3% higher than that of drugs made in emerging economies.
